产品
编 号：F741240
产品类型
规格
价格
是否有货
1mg
询价
询价
结构图
CAS No: 1610943-06-0
产品详情
生物活性：
Emicizumab is a bispecific monoclonal antibody that bridges activated factor IX and factor X to replace the function of missing activated factor VIII, thereby restoring hemostasis. Emicizumab can be used for hemophilia A research.
体内研究：
Emicizumab (1.5-10 mg/kg，静脉注射，尾夹出血前 24 小时)部分纠正血友病a型出血模型中的失血，FVIII 等效为 9 U/dL。Emicizumab (3 mg /kg, 静脉注射) 联合低剂量 FVIII (10 U/dL) 时可提供额外的止血活性。Animal Model:FVIII-deficient mice
Dosage:1.5-10 mg/kg
Administration:IV, 24 hours before tail-clip bleeding was performed
Result:Significantly reduced blood loss in a tail-clip-bleeding model using FVIII-deficient mice.
Emicizumab is a bispecific monoclonal antibody that bridges activated factor IX and factor X to replace the function of missing activated factor VIII, thereby restoring hemostasis. Emicizumab can be used for hemophilia A research.
体内研究：
Emicizumab (1.5-10 mg/kg，静脉注射，尾夹出血前 24 小时)部分纠正血友病a型出血模型中的失血，FVIII 等效为 9 U/dL。Emicizumab (3 mg /kg, 静脉注射) 联合低剂量 FVIII (10 U/dL) 时可提供额外的止血活性。Animal Model:FVIII-deficient mice
Dosage:1.5-10 mg/kg
Administration:IV, 24 hours before tail-clip bleeding was performed
Result:Significantly reduced blood loss in a tail-clip-bleeding model using FVIII-deficient mice.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备